Fust Matthew K
SEC Form 4 insider trading activity
Fust Matthew K has filed 5 SEC Form 4 filings (7 transaction rows) across 3 companies, including CRNX, ATRA, RARE, with disclosures dating back to 2025. 5 of those filings fall inside the rolling window. Most recent filing: Sep 1, 2026.
On the most recent filing, Fust Matthew K is listed as Director at Crinetics Pharmaceuticals, Inc. Inside the rolling window, Fust Matthew K reported no open-market purchases and 1 open-market sale totaling $716K in CRNX.
Companies traded
Other insiders at CRNX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$716K
reported sales (SEC code S)
Companies
3
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Fust Matthew K made?
Fust Matthew K has filed 5 SEC Form 4 filings (7 transaction rows) across 3 companies, including CRNX, ATRA, RARE since 2025.
Which companies does Fust Matthew K trade?
Fust Matthew K has filed SEC Form 4 disclosures for 3 companies, including CRNX, ATRA, RARE.
When was Fust Matthew K's most recent SEC Form 4 filing?
Fust Matthew K's most recent SEC Form 4 filing on Tracefour is dated Sep 1, 2026.
What is Fust Matthew K's total buy and sell value in the current window?
Inside the rolling retention window, Fust Matthew K bought $0 and sold $716K based on SEC Form 4 filings.
What was Fust Matthew K's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 16,000 CRNX shares on 2025-09-26, worth $716K, per SEC Form 4 filings.